Genetic risk test for colorectal cancer (AnteCRC)

From 195.00

Important information

Test results are connected to the e-mail you provide.

Post-test consultation

Test results are explained to you by a medical specialist. if you order multiple tests then you only need one consultation per person.

Additional test

AnteMEL is a melanoma genetic risk test. It is suitable for both sexes.

AnteBC is a breast cancer genetic risk test. It is suitable only for women.

AntePC is a prostate cancer genetic risk test. It is suitable only for men.

Product price: 195.00
Additional options total::
Order total:

What does AnteCRC test include?

  • Analyzes of 91 genetic variants associated with colorectal cancer;
  • Individual polygenic risk score for colorectal cancer;
  • The individual risk of colorectal cancer compared to the rest of the population;
  • Likelihood to get colorectal cancer in 10 years and risk assessment compared to a person with average genetic risk;
  • Interpretation of the test results with clinical recommendations;

Who can benefit from AnteCRC?

  • Men and women between the ages of 40-75.

The AnteCRC test is not recommended:

  • If you have a high-risk mutation in a single gene predisposed to colorectal cancer (e.g. APC, KRAS, TP53, MLH1, MSH2, MSH6, PMS2, STK11, MUTYH).

How AnteCRC test works?

Description of the test is available here
Overview of the test and methodology are available here

AnteCRC Test Limitations

  • AnteCRC test is not used to diagnose colorectal cancer.
  • An elevated risk estimated by the AnteCRC test does not mean that you will develop colorectal cancer during your lifetime. Also, a moderate or lower risk does not mean that the probability of developing the diseases is zero.
  • AnteCRC test does not assess the risk of your family and relatives, i.e. polygenic risk score-based disease risks may not be transmitted directly from parents to children.
  • AnteCRC test does not analyze rare pathogenic mutations in genes that significantly increase the risk of colorectal cancer, such as APC, KRAS, TP53, MLH1, MSH2, MSH6, PMS2, STK11, MUTYH and others.
  • The AnteCRC test is based on the most up-to-date scientific data, which may, however, be supplemented and changed in the future as additional information becomes available. The field of genetics is constantly evolving, which may lead to changes in risk assessments over time, as well as changes in test selection recommendations and clinical recommendations based on test results.
  • Different polygenic risk scores predicting risks of the same trait may give different estimates of the individual’s risks due to differences in the genetic variants included in the models and their weights.
  • The results of this test should be applied in context with other relevant clinical data. In addition to the possible genetic predisposition, other risk factors also influence the risk of colorectal cancer.
/* Omit closing PHP tag at the end of PHP files to avoid "headers already sent" issues. */